Valuation: VolitionRx Limited

Market Cap 11.25M 9.84M 9.09M 8.48M 15.97M 1.06B 16.26M 109M 42.31M 525M 42.25M 41.31M 1.83B P/E 2026 *
-0.61x
P/E 2027 * -0.97x
Enterprise Value 11.25M 9.84M 9.09M 8.48M 15.97M 1.06B 16.26M 109M 42.31M 525M 42.25M 41.31M 1.83B EV / Sales 2026 *
4.54x
EV / Sales 2027 * 1.96x
Free-Float
91.38%
Yield 2026 *
-
Yield 2027 * -
1 day-4.93%
1 week+11.57%
1 month-49.44%
3 months-66.58%
6 months-73.59%
Current year-73.59%
1 week 1.19
Extreme 1.1905
1.43
1 month 1.17
Extreme 1.17
2.6
Current year 1.17
Extreme 1.17
7.73
1 year 1.17
Extreme 1.17
16.39
3 years 1.17
Extreme 1.17
31
5 years 1.17
Extreme 1.17
82.8
10 years 1.17
Extreme 1.17
136.8
Manager TitleAgeSince
Chief Executive Officer 55 06/10/2011
Director of Finance/CFO 56 01/02/2021
Chief Tech/Sci/R&D Officer 49 01/04/2024
Director TitleAgeSince
Chairman 61 06/11/2024
Director/Board Member 55 06/10/2011
Director/Board Member - 30/09/2024
Date Insider Type Main position Quantity % Market Cap.
03-17Tax

Chief Technology Officer

5,310 0.0039%
03-17Tax

Executive/Senior Manager

5,251 0.0039%
03-17Tax

General Counsel

7,003 0.0052%
Change 5-day change 1-year change 3-year change Capi.($)
-4.93%+11.57%-91.12%-95.14% 11.25M
-2.43%+9.18%+117.28%+130.59% 4.69B
+0.23%+24.49%+84.12%+219.67% 3.43B
-2.34%-2.61%-29.56%-41.56% 1.98B
-1.19%-6.31%+141.86%-40.91% 1.86B
-2.66%+13.46%+45.85%+235.29% 1.47B
-2.35%+16.20%+158.92%-49.80% 920M
-2.46%+9.80%-10.27%+44.53% 884M
+6.50%+14.57%+24.77% - 537M
-1.37%-6.40%-38.87%-21.32% 468M
Average -1.16%+7.91%+40.30%+42.37% 1.63B
Weighted average by Cap. -1.25%+9.69%+76.43%+97.79%

Financials

2026 *2027 *
Net sales 2.48M 2.17M 2M 1.87M 3.52M 234M 3.58M 24.01M 9.32M 116M 9.31M 9.1M 403M 5.73M 5.02M 4.63M 4.32M 8.14M 542M 8.29M 55.57M 21.57M 268M 21.54M 21.06M 932M
Net income -22.2M -19.43M -17.94M -16.73M -31.53M -2.1B -32.09M -215M -83.54M -1.04B -83.42M -81.55M -3.61B -19.62M -17.17M -15.85M -14.79M -27.86M -1.86B -28.36M -190M -73.82M -915M -73.71M -72.06M -3.19B
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
67
Date Price Change Volume
30/06/26 $1.350 -4.93% 163,419
29/06/26 $1.420 +10.94% 301,479
26/06/26 $1.280 -0.78% 122,605
25/06/26 $1.290 +4.88% 196,506
24/06/26 $1.230 +1.65% 163,196
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.350USD
Average target price
16.97USD
Spread / Average Target
+1,156.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock